Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472H

Exon 28 polymorphism p.D1472H is associated with significantly lower von Willebrand Ristocetin cofactor activity (VWF:RCoF) to von Willebrand antigen (VWF:Ag) ratio compared to normal, but has been reported as not conferring haemorrhagic risk. The impact of this polymorphism while assessing symptomatic patients for von Willebrand disease (VWD) has not been previously analysed. We retrospectively reviewed charts of children with clinically significant bleeding and abnormal VW panel who underwent VW exon 28 analysis. Twenty‐three of 63 patients studied had p.D1472H. Of these 23 patients, 6 with borderline low VWF:RCo were given provisional diagnosis of VWD type 1 by treating physicians, which could be alternatively explained as due to the effect of p.D1472H. None of the patients with low VWF:RCo, decreased VWF:RCo/VWF:Ag ratio and p.D1472H had VWD type 2M mutations identified. This study illustrates the challenge in diagnosing VWD using ristocetin‐based VW assay in symptomatic patients with p.D1472H.

[1]  R. Hoffmann,et al.  No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. , 2013, Blood.

[2]  F. Peyvandi,et al.  A comparative evaluation of a new automated assay for von Willebrand factor activity , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Di Paola,et al.  Making a diagnosis of VWD. , 2012, Hematology. American Society of Hematology. Education Program.

[4]  C. Casari,et al.  von Willebrand factor: the old, the new and the unknown , 2012, Journal of thrombosis and haemostasis : JTH.

[5]  E. Favaloro,et al.  Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity , 2012, International journal of laboratory hematology.

[6]  Christine A. Lee,et al.  Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[7]  R. Hoffmann,et al.  Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. , 2011, Blood.

[8]  R. Hoffmann,et al.  Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. , 2010, Blood.

[9]  P. Mannucci,et al.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor , 2006, Journal of thrombosis and haemostasis : JTH.

[10]  R. Montgomery,et al.  A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity. , 1982, Blood.